Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8570520 | 0.92 | OPRL1 (0.45) | OPRL1OPRM1CHRM3CHRM2DRD2 | |
| SCHEMBL29445321 | 0.89 | OPRL1 (0.52) | OPRL1OPRM1CHRM3CHRM2DRD2 | |
| SCHEMBL6168606 | 0.89 | OPRL1 (0.52) | OPRL1OPRM1CHRM3CHRM2DRD2 | |
| SCHEMBL8569557 | 0.88 | CHRM2 (0.54) | OPRL1OPRM1CHRM3CHRM2DRD2 | |
| SCHEMBL6164748 | 0.88 | OPRL1 (0.44) | OPRL1OPRM1CHRM3CHRM2DRD2 | |
| SCHEMBL6166931 | 0.88 | CHRM3 (0.43) | OPRL1OPRM1CHRM3CHRM2DRD2 | |
| SCHEMBL8564439 | 0.87 | CHRM2 (0.55) | OPRL1OPRM1CHRM3CHRM2DRD2 | |
| SCHEMBL5113815 | 0.86 | FAAH (0.47) | OPRL1OPRM1CHRM3CHRM2DRD2 | |
| SCHEMBL8571871 | 0.86 | CHRM3 (0.54) | OPRL1OPRM1CHRM3CHRM2DRD2 | |
| SCHEMBL8562946 | 0.86 | CHRM3 (0.54) | OPRL1OPRM1CHRM3CHRM2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329665-B2 | E. g., (+)-3-{1-[3-(2,2,2-trifluoroethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4dihydro-2(1H)-quinazolinone; pollakiuria and urinary incontinence; anticholinergic agents; selective antagonism of the M3 muscarinic receptor which depresses frequency of rhythmic bladder contractions; side effects reduction | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-02-12 | — | — | US | disclosed |
| EP-1424334-B1 | QUINAZOLINONE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20050032819-A1 | Quinazolinone derivative | Sumitomo Pharma Co., Ltd. (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424334-A1 | QUINAZOLINONE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032819-A1 | Quinazolinone derivative | CHRM1, CHRM2, CHRM3 | OPRL1 88/4885OPRM1 27/4885CHRM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.